Home/ Stocks/ VNRX

VolitionRx Limited

VNRX XASE

$2.25 -0.17 (-7.02%) ▼ 15-min delayed

Open

$2.40

High

$2.45

Low

$2.25

Volume

172.3K

Market Cap

$18.20M

About VolitionRx Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Sector: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES Employees: 75 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$1.73M	$-23,503,329	N/A
FY 2025	$1.73M	$-23,503,329	N/A
Q3 2025	$627.3K	$-5,409,791	N/A
Q2 2025	$406.7K	$-6,314,070	N/A

Related Market News

No specific coverage for VNRX yet. Check out our latest market news or earnings calendar.

Get VNRX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on VolitionRx Limited.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.